Simulations Plus, Inc. published a blog post by Dr. Jeremy Jones discussing where mechanistic modeling and AI are intersecting in the discovery space.
Public source
Publisher name
Public post
What if we could predict whether a compound could reach an effective human dose early in the development of a drug? Or perhaps even incorporate that information into the…
Company
Simulations Plus, Inc.
Where are you in the drug development process? Save resources & get to market faster with our solutions!
- Industry
- Software Development
- Location
- Durham, US
- Company size
- 201–500 employees
About Simulations Plus, Inc.
Simulations Plus is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI) and machine learning (ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, and consumer goods companies, and regulatory agencies worldwide. For more information visit us at www.simulations-plus.com
See moreLatest activity
Latest activity from Simulations Plus, Inc.
8 signals
Presence & Recognition
Simulations Plus, Inc. experts Lynzie Worth and Jenna Rouse will be at DPHARM 2026
Presence & Recognition
Simulations Plus, Inc. hosted the workshop titled Biopharma AI Operating Platform and in silico Early-Stage ADME/PK/PD Modeling for Beginners: Introduction to Real-World Application Cases at the Korea Chapter of the Pharmaceutical & BioScience Society International (Korea-PBSS)
Presence & Recognition
Simulations Plus, Inc. hosted Jeremy Jones hosting the ADMETPredictor v14 webinar on September 16 at 11 AM EDT.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
OpenADMET
OpenADMET published a blog post by Cynthia Xu examining the applicability domain (AD) definitions and their correlation with model error.
Research & Knowledge
Instem
Instem published a blog exploring why chemical coverage matters, how applicability domain makes uncertainty more visible, what out-of-domain results mean for ICH M7 assessments, and how model coverage can be expanded without weakening predictive performance.
Research & Knowledge
eClinical Solutions
eClinical Solutions published a new blog by Chief Transformation and AI Officer Venu Mallarapu exploring the disconnect between AI theory and AI practice, including the three layers biopharma companies need to leverage AI in clinical trials, the difficulty of applying these layers in real-world clinical development, and the steps to move from AI ambition to operational readiness.
Research & Knowledge
Apotek Biotechnologies
Apotek Biotechnologies published an article titled Apotek Insights on the context of use, validation, and decision quality of AI in drug development, examining why drug assets need to be evaluated as a whole.
Research & Knowledge
PhoenixBio